Navigation Links
Affymax Reports Phase 2 Clinical Dose Ranging Results of,Once-Per-Month Hematide for the Treatment of Anemia

PALO ALTO, Calif.--(BUSINESS WIRE)--Jun 25, 2007 - Affymax, Inc. (Nasdaq:AFFY) today announced that additional Phase 2 clinical trial results for Hematide(TM) were presented at the European Renal Association-EDTA Congress being held in Barcelona, Spain by Iain C. Macdougall, M.D., a Hematide investigator from Kings College, London. Dr. Macdougall's poster included data in previously-treated dialysis patients and treatment naive, non-dialysis patients which demonstrated that mean hemoglobin (Hgb) levels could be maintained and corrected, respectively, with once monthly Hematide.

Specifically, the data showed that in non-dialysis patients an initial range of doses from .025 mg/kg to .075 mg/kg of Hematide, in conjunction with dose adjustments, is adequate to increase Hgb in anemic patients with renal failure when administered monthly. In addition, intravenous and subcutaneous dosing appeared to result in a similar Hgb increase.

"These data support further investigation of the versatility and flexibility of once-per-month Hematide in terms of starting doses and route of administration," said Robert Naso, Ph.D., executive vice president of Research and Development at Affymax. "These results demonstrate that a narrow target range of hemoglobin levels can be reached with different initial Hematide doses. We are pleased to have such thorough evaluation of the product as we prepare for pivotal Phase 3 clinical trials."

At the time of the presentation, the data generated to date were from two multi-center, open-label studies that have enrolled a total of 304 patients. Safety data were based on the entire patient population, while pharmacodynamic data were based on 179 patients who had mostly completed six months of treatment at European and U.S. clinical sites. Of those, 89 treatment-naive CKD patients who were not on dialysis in the correction study were treated with Hematide once every four weeks. The me
'"/>




Page: 1 2 3

Related medicine technology :

1. Affymax Announces Phase 2 Clinical Trial Results of Once-Per-Month Hematide for the Treatment of Anemia in Patients with Early- and End-Stage Chronic Kidney Disease
2. Affymax Announces Results From Phase 2 Clinical Trial of Hematide for the Treatment of Anemia in Dialysis Patients
3. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
4. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
5. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
6. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
7. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
8. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
9. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
10. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
11. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
Post Your Comments:
(Date:12/16/2009)... According to Millennium Research Group (MRG), the global ... reforms in China supported rapid expansion of the ... continue to fuel growth in the coming years. ... Interventional Cardiology Devices 2010 report finds that ... the Chinese drug-eluting stent market to reach a ...
(Date:12/16/2009)... -- Today, Avantium announced the,appointment of Gunnar ... pharmaceutical,business. Gunnar Staaf previously worked at Serentis ... Company, in a range of commercial and ... in Avantium,s plan to,spin-out its pharmaceutical business. ... company based on its offering of proprietary,crystallization ...
(Date:12/16/2009)... Dec. 16 Vivakor, Inc. (OTC ... Development agreement with Baker Consulting out of ... Kyouko Group, Inc. out of South Florida. ... Vivakor to assist with business development, financing ... reported acquisition strategy. Specifically, Baker Consulting is ...
Breaking Medicine Technology:Major Health Care Reforms in China Supported Growth of More Than 20% in the Drug-Eluting Stent Market in 2009, According to Millennium Research Group 2Major Health Care Reforms in China Supported Growth of More Than 20% in the Drug-Eluting Stent Market in 2009, According to Millennium Research Group 3Avantium Appoints Gunnar Staaf as CEO Pharma 2Vivakor Signs Business Development Agreement With Baker Consulting 2Allscripts and Medfusion Partner to Provide Patient Portal to Physician Practices Nationwide 52292 1Allscripts and Medfusion Partner to Provide Patient Portal to Physician Practices Nationwide 52292 2Allscripts and Medfusion Partner to Provide Patient Portal to Physician Practices Nationwide 52292 3Allscripts and Medfusion Partner to Provide Patient Portal to Physician Practices Nationwide 52292 4RF Technologies Achieves Premier Certification From Cisco in United States 52288 1RF Technologies Achieves Premier Certification From Cisco in United States 52288 2Parental Stress Boosts Kids Asthma Risk 52283 1Parental Stress Boosts Kids Asthma Risk 52283 2Parental Stress Boosts Kids Asthma Risk 52283 3
(Date:12/16/2009)... never felt so good for "The Biggest Loser" Danny ... continuing to make smart choices everyday to help him ... choice that is an important part of living well. ... glass of milk has nine essential nutrients like protein ... pressure, and calcium and vitamin D for strong bones. ...
(Date:12/16/2009)... -- For wounded U.S. servicemen and women ... D.C., the holidays can be a particularly difficult time. ... rely more than ever on the healing power of ... home just got easier for Walter Reed patients as ... will provide hundreds of minutes of holiday talk time ...
(Date:12/16/2009)... a result of C3: Colorectal Cancer Coalition,s advocacy efforts, ... program is included in the final Fiscal Year 2010 ... program will research cancers, like colorectal cancer, that are ... cancer research programs run by the U.S. Army Medical ... million in funding for this new cancer research program ...
(Date:12/16/2009)... deadly, attack is long-term goal, researchers say , , ... a tool to predict whether a patient will suffer ... stroke. , "This is an important new tool because ... stroke soon after a first stroke are more likely ... of Massachusetts General Hospital and Harvard Medical School, said ...
(Date:12/16/2009)... it plays a role in reducing inflammation in the ... gene variant that plays a role in inflammation seems ... well as adults who smoke. , Researchers also found ... gene had a lower risk of developing chronic obstructive ... by smoking. , "The gene seems to be protective ...
Breaking Medicine News(10 mins):Health News:Verizon Wireless Donates $10,000 in Long-Distance Calling Cards to Soldiers at Walter Reed Hospital 2Health News:House Creates New Cancer Research Program 2Health News:House Creates New Cancer Research Program 3Health News:New Stroke Tool May Predict Early Recurrence 2Health News:Gene Variant Seems to Guard Against Asthma, COPD 2Health News:Gene Variant Seems to Guard Against Asthma, COPD 3
... (H 2 S) is a gas most commonly associated with ... a team of researchers from the Peninsula Medical School in ... now identified a role for this gas in regulating blood ... journal Circulation. , The research team has previously shown that ...
... Physicians (ACP) -- the nations second-largest medical society ... -- a continuing medical education (CME) meeting for ... provide primary and subspecialty care to adult patients. ... health professionals, medical residents, fellows, and students. Internal ...
... at Johns Hopkins have outlined a new path for ... asthma based on a new understanding of the bodys ... , Researchers say their findings, to be published ... and Clinical Immunology, are the first evidence describing how ...
... care and enhance ... 10 Florida locations, TAMPA, Fla., April 29 ... patient care delivery and,business office processes, Florida Cardiology, a ... Intergy EHR by,Sage Electronic Health Records and Intergy by ...
... UNDER LYME, UK, April 29 /PRNewswire-FirstCall/ - Traxxec,Ltd, ... (Pink Sheets OTC -,CRVR.pk), today announces that, in ... technology is being presented at the Interpack conference,and ... pharmaceutical and packaging companies will be present at ...
... NEW YORK, April 29 Flashpoint Medica, a ... Omnicom Group,(NYSE: OMC ), was named Agency ... at the publication,s annual Manny Awards ceremony held,April ... thinking, powerful creative, and a,collaborative approach to strategy ...
Other Medicine News:Health News:'Rotten eggs' in the blood 2Health News:Internal Medicine 2008 media advisory 2Health News:Immune system kick-started in moist nasal lining in sinusitis, asthma and colds 2Health News:Immune system kick-started in moist nasal lining in sinusitis, asthma and colds 3Health News:Florida Cardiology Chooses Intergy by Sage to Integrate Practice Management and Electronic Health Records 2Health News:Florida Cardiology Chooses Intergy by Sage to Integrate Practice Management and Electronic Health Records 3Health News:Columbia River Resources Inc subsidiary, Traxxec Ltd, reports coverage of its technology at Interpack 2008 (Pink Sheets OTC - CRVR.pk) 2Health News:Columbia River Resources Inc subsidiary, Traxxec Ltd, reports coverage of its technology at Interpack 2008 (Pink Sheets OTC - CRVR.pk) 3Health News:Flashpoint Medica Named Agency of Year by Medical Advertising News 2
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 7.0 mm and length 7.7 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 8.0 mm and length 5 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 13.0 mm and length 12 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Standard type 1/1 (mm), opening width 9.0 mm and length 6 mm....
Medicine Products: